NEW YORK (GenomeWeb) – An international team of researchers has used a CRISPR activation (CRISPRa) screen to identify both coding and noncoding pathways involved in acquired resistance to cytarabine, the main treatment for acute myeloid leukemia (AML).

The study, led by senior author Pier Paolo Pandolfi of the Beth Israel Deaconess Medical Center and Harvard Medical School, was published in Cell today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.